Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

Source link

Related posts

Treating HCV in prison ‘microenvironment’ reduces transmission


Poxel announces favorable safety, tolerability of NASH therapeutic


Drugs Helped Stop Weight Regain After Gastric Bypass


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy